Perspectives of People With HIV-1 24 Months Following a Switch to Cabotegravir and Rilpivirine Long-Acting (CAB + RPV LA) in an Observational Real-world US Study (BEYOND)

Conference Reports for NATAP

IAS 2025, 13th IAS Conference on HIV Science
Kigali, Rwanda
July 13-17


Perspectives of People With HIV-1 24 Months Following a Switch to Cabotegravir and Rilpivirine Long-Acting (CAB + RPV LA) in an Observational Real-world US Study (BEYOND)

	13th IAS Conference on HIV Science; July 13-17, 2025; Kigali, Rwanda Franco Felizarta,1 IAS: Clinical Outcomes at Month 24 After Initiation of Cabotegravir and Rilpivirine Long Acting (CAB+RPV LA) in an Observational Real-World Study (BEYOND) - (07/18/25)